Perrigo has announced the US launch of a new over-the-counter (OTC) generic version of the oral proton pump inhibitor therapy Nexium.
The therapy, designed to calm the production of acid in the stomach, is used to treat a number of different conditions, including gastroesophageal reflux disease, stomach ulcers, and heartburn associated with acid reflux disease.
“Perrigo has launched a new generic over-the-counter version of the proton pump inhibitor therapy Nexium.“
This represents the first-to-market OTC store brand equivalent of the 24-hour capsule therapy, with products packaged and marketed as store brands or retailer own-label brands. It offers a high-quality, value alternative to the established version of Nexium.
Nexium generated approximate retail sales in excess of $300 million (225.9 million pounds) in the last 12 months, showing that a significant market opportunity exists for a lower-cost generic version.
Jeff Needham, Perrigo's executive vice-president and president for consumer healthcare in the Americas, said: "We remain committed to providing innovative OTC products that meet our customers' needs, while serving consumers and patients with high-quality, value alternatives that lower the cost of healthcare."
With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Consumer